Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01512797 · ClinicalTrials.gov registry record · NA
Treatment of Diabetes After Gastric Bypass With Sitagliptin
A NA study, sponsored by Blandine Laferrere.
- Completed
- Registry status
- NA
- Development phase
- 37
- Enrollment target
NCT01512797: Completed NA study, sponsored by Blandine Laferrere.
NCT01512797 is a NA study that has completed, run by Blandine Laferrere. The registered enrollment target is 37 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01512797, a NA study, has completed, sponsored by Blandine Laferrere.
- COMPLETED
- Registry status
- NA
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether Januvia (sitagliptin phosphate 100mg) is safe and effective for the treatment of Type 2 Diabetes in patients who have had Gastric Bypass.
Primary Outcome
Glucose levels were measured in study participants while fasting and periodically over 3 hours after drinking a 200 kcal mixed meal test, before and after intervention (Sitagliptin or Placebo).
Interventions
- OTHER Placebo
- DRUG Sitagliptin phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2012-07 |
| Est. Completion | 2016-08 |
| Phase | NA |
What the finished NCT01512797 record still lists
NCT01512797 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01512797 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01512797 about?
NCT01512797 is a clinical study titled "Treatment of Diabetes After Gastric Bypass With Sitagliptin". The purpose of this study is to assess whether Januvia (sitagliptin phosphate 100mg) is safe and effective for the treatment of Type 2 Diabetes in patients who have had Gastric Bypass.
What is the current status of trial NCT01512797?
This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2012-07. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01512797?
The interventions under investigation include: Placebo (OTHER), Sitagliptin phosphate (DRUG).
Who is sponsoring clinical trial NCT01512797?
This trial is sponsored by Blandine Laferrere, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01512797's enrollment target sits among peer trials
37 1540th of 2000 higher than 460 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia